^
Association details:
| Biomarker: | ROS1 rearrangement + PD-L1 overexpression |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Regimen: | ABCP (Avastin (bevacizumab) + carboplatin + paclitaxel + Tecentriq (atezolizumab)) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Response to ABCP Regimen in a ROS1Rearranged Lung Adenocarcinoma Patient with Brain Metastases and High PD-L1 Expression: A Case Report
Published date:
11/29/2022
Excerpt:
We report a case of a 42-year-old female with ROS1-rearranged NSCLC and high PD-L1 expression treated with atezolizumab (1200 mg) / bevacizumab (7.5 mg/kg) / carboplatin (AUC 5) / pemetrexed (500 mg/m2) (ABCP) regimen after failure of targeted therapy. After 2 cycles, she achieved partial response (PR) and confirmed PR after 4 cycles of ABCP regimen not only in the primary lung lesion, but also in multiple metastatic lesions of the brain.
DOI:
https://doi.org/10.29011/2574710X.10151
